Quintiles Data Management to Conduct 200th EDC Trial

Research Triangle Park, North Carolina (ots/PRNewswire) -

- Emerging U.S. company Aerovance Inc. studying COPD drug in U.K.

Quintiles Transnational Corp. today announced that it has reached
a significant milestone in data management -- the 200th clinical
trial using Electronic Data Capture (EDC).

Quintiles is using EDC in a trial being conducted in the United
Kingdom for Aerovance, Inc., of Berkeley, Calif., which is studying a
drug candidate for chronic obstructive pulmonary disease. Quintiles
began using EDC in 1999 and has seen the acceptance of EDC accelerate
since then, with more than 60 EDC trials put into production in 2005.

"This achievement is important for Quintiles as well as the
pharmaceutical and biotechnology industries because it indicates the
increasing recognition of the tangible benefits of EDC," said Paula
Brown Stafford, Executive Vice President, Global Data Management,
Quintiles. "As the leader in outsourced EDC services, we are seeing
greater appreciation for the potential savings in time and expense,
as well as the ability to provide better access to data throughout
the length of the study.

"We are thrilled to work again with Aerovance, an emerging
biopharmaceutical company that is conducting important research into
serious respiratory and inflammatory diseases. Quintiles looks
forward to bringing Aerovance our expertise managing electronic
patient data."

Quintiles also is conducting EDC studies for Aerovance in the
treatment of cystic fibrosis, asthma and eczema.

"Quintiles Data Management has developed an elegant clinical EDC
program for us," said Richard Fuller, Chief Operating Officer,
Aerovance. "We turned to Quintiles because of the good experience we
had working with them before, as well as their flexibility, which
allows them to work with an emerging biotech like us just as they
would with a major pharmaceutical company."

About Aerovance

Aerovance is a privately held biopharmaceutical company focused
exclusively on the development and commercialization of biologics for
severe respiratory and inflammatory diseases such as asthma, cystic
fibrosis (CF), chronic obstructive pulmonary disease (COPD) and
eczema. The company's two lead products are AER001, an IL4/13
receptor antagonist for severe asthma and eczema currently in Phase 2
studies, and AER002 a recombinant protein for CF and COPD currently
in Phase 2 studies. In addition to these investigational products,
Aerovance has several preclinical programs in respiratory disease.
Aerovance was spun off from Bayer Pharmaceuticals' biotechnology unit
in August 2004.

About Quintiles Global Data Management

Quintiles Global Data Management delivers consistent, accurate
data through flexible and cost-effective solutions for customers.
Services include capturing, analyzing and reporting patient-related
data traditionally, by paper and fax, or electronically, by EDC and
PDA, and then integrating data into a clean, compatible and fully
CDISC-compliant database to facilitate regulatory submission and
acceptance. Quintiles Global Data Management has more than 1,000
employees in 10 offices around the world.

About Quintiles

Quintiles is the global leader in pharmaceutical services,
improving healthcare worldwide by providing innovative, quality
professional expertise, market intelligence and partnering solutions
to meet the dynamic needs of the pharmaceutical, biotechnology and
healthcare industries. Quintiles has 16,000 specialized employees and
offices in 50 countries. For more information visit the company's Web
site at http://www.quintiles.com.

Web site: http://www.quintiles.com

ots Originaltext: Quintiles Transnational Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Dick Jones, Media Relations, +1-919-998-2091, or
media.info@quintiles.com, or Greg Connors, Investor Relations,
+1-919-998-2000, or invest@quintiles.com, both of Quintiles
Transnational Corp.